Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Geron CorporationNASDAQ: GERN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $51.84M rose 30.9% year over year, behind the +68.6% change in trailing-twelve-month revenue. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +575.7% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $235.25M (+27.9%) for the fiscal year ending Dec 2026, a slowdown from the +138.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $51.84M+8.0% QoQ
- Last fiscal yearDec 2025
- $183.88M+138.8% YoY
- LTMMar 2026
- $196.12M+68.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.9% | +12.8% | -18.1 pp |
| 1 year | +138.8% | +27.9% | -110.9 pp |
| 3-year CAGR | +575.7% | +39.8% | -535.9 pp |
| 5-year CAGR | +31.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 183.88M USD
- Year-over-year change
- +138.8%
- 4-year CAGR
- +239.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 183.88M | +138.8% |
| FY2024 | 2024-12-31 | 76.99M | +32386.9% |
| FY2023 | 2023-12-31 | 237K | -60.2% |
| FY2022 | 2022-12-31 | 596K | -57.2% |
| FY2021 | 2021-12-31 | 1.39M | — |
Revenue vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 revenue of $196.12M is the 3rd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of +68.6% is the highest of 4, against a peer median of +26.9%.
- Over three fiscal years its annual growth of +575.7% compares with a peer median of +24.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $5.82B | +26.9% | +14.8% | |
| LTM Mar 2026 | $299.77M | +47.6% | +34.8% | |
| LTM Mar 2026 | $196.12M | +68.6% | +575.7% | |
| LTM Jun 2026 | $35.09M | — | -55.6% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $0 | — | — |
| LTM Sep 2026 | $0 | — | — | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | -100.0% | +175.9% | |
| Peer median (excluding GERN) | $0 | +26.9% | +24.8% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39M | 596K | 237K | 76.99M | 183.88M |
| Cost of Revenue | 0 | 0 | 0 | 1.26M | 4.75M |
| Gross Profit | 1.39M | 596K | 237K | 75.74M | 179.14M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.4% | 97.4% |
| Research & Development | 85.73M | 95.52M | 125.05M | 103.74M | 73.72M |
| Selling, General & Admin | 29.67M | 43.63M | 69.14M | 145.73M | 159.26M |
| Operating Expenses | 115.39M | 139.15M | 194.18M | 249.47M | 232.97M |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| EBITDA | (111.59M) | (134.15M) | (174.78M) | (154.85M) | (51.92M) |
| EBITDA Margin | -8010.7% | -22508.6% | -73747.7% | -201.1% | -28.2% |
| Operating Income | (114M) | (138.55M) | (193.94M) | (173.73M) | (53.84M) |
| Operating Margin | -8183.7% | -23246.6% | -81832.9% | -225.6% | -29.3% |
| Interest Income | 527K | 2.53M | 18.15M | 19.61M | 18.12M |
| Interest Expense | 3.74M | 6.88M | 8.31M | 18.5M | 32.66M |
| Other Income / Expenses | (2.11M) | (3.35M) | 9.82M | (840K) | (31.95M) |
| Income Before Tax | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Pre-Tax Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Net Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| EPS (Basic) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| EPS (Diluted) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| Weighted Avg Shares | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
| Weighted Avg Shares (Diluted) | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.